arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

CITIUS ONCOLOGY, INC.

CTOR

$0.78 ▲ +0.03 (+3.35%) at close

5 Visible periods

17 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

CITIUS ONCOLOGY, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $57.1M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -54.8% ↘

FCF / Share $-0.07 ↘

Trailing P/E —

Price / Book 1.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

5-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-24.76M

↓ -17.1% —

FCF / Share Free cash flow per share

$-0.07

↓ -4137.2% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 2 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
EPS Growth YoY (%)	-9.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-63.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	—
Net Income Growth YoY (%)	-17.1% Weak Weak Year-over-year change in net income	-66.6% Weak Weak Year-over-year change in net income	N/M	N/M	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Effective Tax Rate (%) (%)	-4.5% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-2.8% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-4.8% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
FCF / Net Income (x)	0.22x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-0.01x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	-0.13x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Return on Invested Capital (%)	-54.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-45.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	—	-31.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	79.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%
Return on Capital (%) (%)	-23.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-24.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	—	-0.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-8.0% Weak Weak Operating profit relative to total assets Optimal: > 10%
Return on Common Equity (%) (%)	-55.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-468%)	-45.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-406%)	-49.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-431%)	110.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+635%)	100.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+567%)

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Interest Coverage (x)	-107.89x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Basic EPS, GAAP (USD)	$-0.34	$-0.31	$-0.19	$0.12	$-0.01
Free Cash Flow per Share (USD)	$-0.07	$0.00	—	$-0.04	—
Book Value per Share (USD)	$0.54	$0.64	$0.38	$0.14	$-0.00
Tangible Book Value per Share (USD)	$0.54	$0.64	$0.38	$0.14	$-0.00
Basic Weighted Avg Shares (shares)	73.27M	68.05M	67.50M	1.34M	1.73M

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Working Capital (USD)	$-21.95M	$-21.73M	$-13.31M	$345.51K	$-10.11K
Total Equity (USD)	$44.87M	$46.14M	$25.54M	$345.51K	$-10.11K

📋 What is driving earnings? 2 metrics

Metric	FY 2025 Sep 30, 2025 10-K ↗	FY 2024 Sep 30, 2024 10-K ↗	FY 2023 Sep 30, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Net Income, GAAP (USD)	$-24.76M	$-21.15M	$-12.70M	$380.81K	$-10.11K
Operating Cash Flow (USD)	$-5.49M	$126.35K	—	$-47.97K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 21 quarters

CITIUS ONCOLOGY, INC.

Analytical Summary

5-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CTOR with peers